Last reviewed · How we verify

VPM1002 — Competitive Intelligence Brief

VPM1002 (VPM1002) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated recombinant vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated recombinant vaccine Mycobacterium tuberculosis antigens (Ag85B, TB10.4) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

VPM1002 (VPM1002) — Serum Life Science Europe GmbH. VPM1002 is a live attenuated recombinant tuberculosis vaccine that enhances immune response by expressing listeriolysin O to improve intracellular antigen presentation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
VPM1002 TARGET VPM1002 Serum Life Science Europe GmbH phase 3 Live attenuated recombinant vaccine Mycobacterium tuberculosis antigens (Ag85B, TB10.4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated recombinant vaccine class)

  1. Serum Life Science Europe GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VPM1002 — Competitive Intelligence Brief. https://druglandscape.com/ci/vpm1002. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: